Medications that treat overactive bladder (OAB) have notorious side effects such as dry mouth, constipation, and urinary retention. Womens Excellence in Bladder Control is now trialing and sampling a brand new medication that treats OAB differently. Shelby Township, Michigan (PRWEB) February 20, 2013 Anticholinergic medications used to treat OAB can cause a variety of unpleasant side effects. In most patients, these side effects are mild and tolerable, but in some patients may be severe and intolerable. Common side effects caused by anticholinergic medications include: dizziness, constipation, urinary retention, and dry mouth. These side effects can be severe enough to cause a patient to quit the medication leaving them with no other oral medication option till now. Astellas pharmaceuticals has recently put on the market a new medication to treat OAB, its called Myrbetriq (mirabegron). The agent is as unique as its name and might just become a go to medication for those patients who fail traditional anticholinergic OAB therapy. Myrbetriq is not an anticholinergic drug. It is a beta-3 adrenergic agonist but relaxes the bladder smooth muscle just as anticholinergics do. Myrbetriq can help with symptoms of urge incontinence, urgency, and frequency. It also helps to increase the bladders capacity … Continue reading →

Dallas, TX (PRWEB) February 20, 2013 The birth control resource center at DrugRisk.com is alerting women who have used NuvaRing contraceptive devices of new safety warnings added to the site. Also, complaints to the FDA over the devices continue to rise as trials are set to begin this summer for more than 1,000 cases. DrugRisks mission is to improve patient safety by providing the latest drug warnings, recalls, studies and litigation news. Weve noticed an increase in both injury claims and complaints to the FDA related to NuvaRing following the recent blood clot warnings, explains DrugRisk representative Ryan Mayer. The resource center previously added warnings which link vaginal ring contraceptives such as NuvaRing to higher risks of blood clots than traditional birth control pills. On June 14, 2012, the New England Journal of Medicine published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots.* DrugRisk has also discovered that the FDA has received nearly 5,500 adverse event reports of complications among women using NuvaRing devices.** Most common were 1,177 reports of pulmonary embolism and 806 reports of deep vein thrombosis, with hospitalization resulting in over 30% of cases.** The resource center … Continue reading →

New York, NY (PRWEB) February 20, 2013 The birth control resource center at DrugRisk.com is alerting women using the IUD contraceptive Mirena of updated legal news added to the site showing a federal court will meet next month to decide the fate of the growing Mirena litigation. DrugRisks mission is to improve patient safety by providing the latest drug warnings,recalls, studies and legal news. This allows users to have informed discussions with their doctors about drug side effects and decide if they need legal advice, explains DrugRisk representative Ryan Mayer. DrugRisk has added information from the FDA showing more than 47,000 patients have filed AERS reports after suffering complications from the Mirena IUD.* Of these, 5079 involved dislocation and 1421 involved migration of the devices, which can perforate or damage the uterine wall.* In more than 6% of cases, patients required hospitalization or surgery. The resource center has also learned that the FDA warned Bayer, the maker of Mirena, about the marketing of the device in 2009, after they failed to disclose safety risks while claiming the devices could help busy moms with intimacy and make them look and feel great.** DrugRisk reported that, with litigation over Mirena perforation growing, … Continue reading →

Methamphetamine crystals in a bag. (AP Photo/DEA) Some of the negative side effects of taking methamphetamines begin only after users have stopped taking them, according to a recent study by University of Florida researchers. A study led by Dr. Habibeh Khoshbouei, an associate professor of neuroscience and psychiatry at the UF College of Medicine, showed that mice withdrawing from methamphetamines had memory loss and a decrease in neuronal activity two weeks after the withdrawal began -- the equivalent of one year in humans. The mice did not have the same symptoms while they were still taking the drugs. It is very well established that people who abuse meth show symptoms of neurodegeneration and psychosis, so long-term meth abuse can produce all sorts of problems, Khoshbouei said. Meth induces an uncontrolled release of dopamine, a neurotransmitter responsible for pleasure. It exposes the brain to too much dopamine, which feels good at the time but has both immediate and long-term consequences namely of killing neurons, said Dr. Jamie Smolen, an addiction psychiatrist at UF. Smolen added that the long-term use of meth might change receptors in the brain permanently, impairing memory, attention span and what is called executive function, or the ability … Continue reading →